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Abstract 
 
The interest in small rodents as companion animals has been increasing, but their short 
longevity has been a difficult obstacle to overcome. One of the pathologies that most frequently 
affects rats are mammary tumors, but although this area is highly developed in laboratory animals 
(induced tumors), little is known about spontaneous mammary tumors in pet rats.  
The rat has six pairs of mammary glands and females are most prone to develop mammary 
tumors than males, particularly fibroadenomas.  
To better understand the pathophysiology of the mammary tumors, we decided to review the 
anatomy, histology and physiology of rats’ mammary glands, as well as the most common clinical 
signs, means of diagnosis and differential diagnoses, treatments and prevention strategies, in 
order to systematize the knowledge about this common pathology. 
We realize that surgical treatment is available, but as recurrences are very frequent its 
effectiveness is limited. As for pharmacological treatment, there are some options but their 
effectiveness lacks proof, so it is necessary to carry out further studies to test new drugs that can 
stop tumor evolution.  
In this scenario, prevention remains the most effective weapon but has been neglected, so 
owners should be advised to timely spay their pets in order to reduce the probability of mammary 
tumor appearance. 
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AB      Alveolar Buds 
Bid      Twice a day 
cAMP      Cyclic Adenosine Monophosphate 
CL      Corpus Luteum  
ER      Estrogen Receptor 
EV                                                                   Endovenous 
FSH      Follicle-stimulating Hormone 
GAS      Gamma Interferon Activated Site  
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PIF      Prolactin Inhibition Factor 
PR      Progesterone Receptor 
PRF      Prolactin Releasing Factor 
PRLR      Prolactin Receptor 
SC      Subcutaneous 
SID      Once a day 
SP      Sprague-Dawley strain 
TD      Terminal Ductules 
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INTRODUCTION 
 
Over the decades, rats have been used as laboratory animals and serve as model for the study 
of the most varied human pathologies. However, in the last years, this species has conquered its 
place as a companion animal.  
 They are highly intelligent, affable and easily become the ideal pet for those who do not spend 
much time at home and appreciate rodents. Some of the main physiological parameters are 
described in table 1. 
However, due to their short average life expectancy, the incidence of mammary tumors 
increases from 18 months. Other factors can potentiate its onset, like high levels of circulating 
prolactin and estrogen, as estrus cycle occurs each 4-5 days.  
One pathology that elevates the level of prolactin is hypophysary adenoma, which is seen in 
many necropsies along with mammary tumor, although the relation between both has not been 
yet proven. Mammary tumor diagnosis is usually presumptive, since excised tumors are not often 
analyzed by histopathology and are most likely to be benign.  
Cytology as diagnosis method is normally useless, and since mammary tumors tend to be 
small sized, histopathology is the gold standard method. 
Treatments are limited, and veterinarians should encourage owners to focus on prevention, 
particularly in ovariohysterectomy in young rats. In addition, surgery, hormone implants, 
chemotherapy, and prolactin antagonists are available options, although more studies are 
needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Average Life Span (years) 2-3 
Weight (g)      Females and Males 250-1000+ 
Body Temperature (ºC) 37-38 
Respiratory Rate (breaths/min) 70-150 
Heart rate (beats/min) 300-450 
Gestation (days) 19-21 
Average number of pups 10-12 
Age at weaning (days) 20-22 
Sexual Maturity (weeks) 5-6 
Table 1 - Physiological parameters of Rattus norvegicus 
Source: Adapted from Exotic Animal Medicine: A quick reference 
guide (2009) 
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Rat mammary gland anatomy and histology 
 
The adult rat (Rattus norvegicus) has six pairs of mammary glands: cervical, cranial thoracic, 
caudal thoracic, abdominal, cranial inguinal and caudal inguinal glands1. The cervical glands 
extend anteriorly to the salivary glands, and the caudal inguinal glands extend to the perianal 
region. Between the cervical and thoracic mammary glands is the muscle pectoralis, which is not 
present in the abdominal and inguinal mammary glands2. The thoracic, abdominal, and inguinal 
glands vary in their degree of development, with the caudal inguinal gland being the most 
differentiated, and the cervical glands being the least differentiated in the nulliparous rat3,4.  
In lactating rats, the glands can extend laterally to both sides of the body1 (Figure 1). 
 
Each mammary gland is composed of epithelium, adipose tissue and connective tissue stroma, 
which has blood vessels, nerves, smooth muscle fibers, lymphatic nodes and lymphatic vessels 
and near the nipple, keratinized epithelium and sebaceous and sweat glands5. 
Lymphatic vessels are lined by a luminal layer of simple squamous endothelium, have a large 
lumen relative to the thickness of the wall and are lined by a discontinuous basement membrane. 
Unlike blood vessels, lymphatics do not convey red blood cells and are difficult to distinguish in 
histological sections when the cross section contains lymphatic vessels with no leukocytes5. 
Mammary gland is a tree-like ductal system, with tubuloalveolar morphology in female and 
lobuloalveolar in males2 (Figure 2). 
Figure 1 - Localization of the 
mammary glands: 1: Cervical; 2: 
Cranial thoracic; 3: Caudal 
thoracic; 4: Abdominal; 5: Cranial 
inguinal; 6: Caudal inguinal. 
Source: Comparative Anatomy and 
Histology: a mouse, rat, and human 
atlas, 2nd edition. 
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In this tree-like ductal system, all the alveoli, ductules and ducts merge into one primary 
collecting duct whose lumen is contiguous with the external surface of the nipple1,2. 
As described above, mammary glands are highly vascularized by branches of several arteries, 
such as superficial cervical, axillary, thoracic internal and external and external pudendal.  
Capillaries change dramatically during development, forming extensive capillary beds in the 
intralobular compartment during pregnancy and lactation6,7,8. 
Female gestation ranges 19-21 days, and the foetus mammary glands development begins 
approximately at 11 day of gestation. Cellular clamps proliferating from two longitudinal crests of  
ectoderm, parallel to the middle line, give origin to six pairs of mammary glands in the adult rat 
(Figure 3).   
 
The regulators of mammary gland morphogenesis include hormones, growth factors and 
receptors, cell cycle regulators and adhesion molecules9. The biggest growth occurs between the 
birth and puberty. The rat reaches puberty approximately at 5-6 weeks of age1. 
There is an accumulation of subcutaneous adipose tissue from the cervical region until the 
inguinal region, creating mammary fat pads and support for the mammary glands. The growth of 
the mammary gland starts from the nipple and progress into the fat pad9. These fat pads are 
composed by preadipocytes, adipocytes and fibroblasts and a thin layer of collagenous stroma 
separates it from the epithelial cells1,10,11,12. Most adipocytes in the rat mammary gland are 
unilocular.  
Mammary gland can be divided into two compartments: the epithelial compartment and the 
stromal compartment2,6. The parenchymal compartment of the mammary gland is composed of 
Figure 2 - Histologic 
differences in mammary 
gland of sexually mature 
rats.  
Source: Comparative 
Anatomy and Histology: a 
mouse, rat, and human 
atlas, 2nd edition. 
 
 
Figure 3 - Downgrowth of 
epithelium from the mammary 
streak in an 18-day-old fetal 
Wistar Han rat. 
Source: Boorman’s Pathology of 
Rat, 2nd edition. 
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different epithelial structures with distinct morphologies, functional and proliferative activities, 
comprising the luminal epithelium of ducts, ductules, terminal end buds, alveolar buds, and 
alveoli, as well as the underlying myoepithelial layer13. This myoepithelial layer can be stained 
with cell markers such as smooth muscle actin and form a thick and continuous layer at the base 
of ducts7,14.  
Myoepithelial cells express higher levels of cell adhesion receptors and adhesion-associated 
molecules than the luminal epithelium and can be distinguished immunohistochemically from 
luminal epithelial cells by their expression of the intermediate filament proteins vimentin and 
cytokeratins 5 and 14, the basement membrane proteins collagen type IV and laminin, and the 
contractile proteins myosin and smooth muscle actin15,16,17,18. 
The luminal epithelium is the epithelium whose apical surface contacts the lumen of ducts, 
ductules and alveoli while the myoepithelium consists of the basal epithelial cells that surround 
the luminal epithelium in all those structures14,19. The luminal epithelium can also be defined 
immunohistochemically by its expression of cytokeratins 8, 18, and 19 in the rat16,17 (Figure 4).  
 
At the end of the first week, each mammary gland has one main lactiferous duct and three to 
five secondary ducts1. These ductal systems are surrounded by adipose tissue, poor in fibrous 
connective tissue. The duct of female has a more prominent lumina, lined by one or two layers of 
regular cuboidal cells or columnar epithelium underlain by myoepithelial cells, compared with the 
indistinct lumina and vacuolated pseudostratified epithelial cells of the lactiferous duct of the 
male1,2. Also, the primary duct is more regular in circumference than the lactiferous sinus but is 
likewise surrounded by a thick layer of connective tissue.  
At the end of second week, secondary ducts branch into tertiary, quaternary and quinary 
ducts1. These ducts will end in terminal end buds (TEBs), which are the growing end of the 
mammary tree2. They are solid or semisolid bulbous clusters of immature epithelial cells at the 
ends of ducts6,20. 
Figure 4 - Basal and luminal cell 
immunohistochemical markers in the mouse 
mammary gland. (A) Immunohistochemistry 
highlights the basal (brow labelling) and luminal 
(blue labelling) cell populations in these low-
magnification images of a mouse pre-lactating 
lobular-acinar unit. (B) Cytokeratin 8/18 labelling 
of luminal epithelial cells (brow labelling). 
Source: Comparative Anatomy and Histology: a mouse, 
rat, and human atlas, 2nd edition. 
(A) 
(B) 
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Each TEB is composed of a central body surrounded by a single layer of pluripotent epithelial 
cells, and surrounding the TEB are host inflammatory cells, giving the appearance of “fuzzy halos” 
in histological preparations2 (Figure 5). These structures are clinical important because they are 
believed to be the most susceptible targets for chemical carcinogens3,21.  
 
The number of TEBs reaches a maximum and then, at 20 days of age, TEBs can cavitate to 
form terminal ductules (TDs) or give rise to alveolar buds (AB)1,22,23. 
Terminal ductules are composed of luminal epithelium and myoepithelium and therefore, lacks 
the multiple-layered epithelium associated with the TEB. When multiple TDs with small lumina 
are clustered in an island of connective tissue, they are referred to as an AB20.  AB are composed 
of one or two layers of cells. The cells lining the lumina are cuboidal or columnar with a round or 
oval nucleus. Myoepithelial cells are present but vary in number and do not form a complete 
layer1. It is correct to say that TEBs and AB are the major sites of morphogenesis and cellular 
differentiation of the mammary glands. Hvid et al. observed that proliferation of the mammary 
epithelium in young rats was mainly in the TEBs whereas proliferating cells were more equally 
distributed in the different compartments of the mammary gland of mature animals24 (Figure 6).  
Puberty, defined as the onset of estrus cycles, commences in the rat between days 35 and 42 
of age. At that time, AB undergo differentiation into alveoli to form alveolar lobules. Each AB 
develops into 10-12 alveoli to form a lobule1 (Figure 7). The shape of the luminal epithelial cell 
ranges from pyramidal (before secretion) to flattened (after secretion) in alveoli and this secretory 
epithelium is responsible for milk synthesis and secretion during lactation7. An outer discontinuous 
layer of fully differentiated myoepithelial cells surrounds the luminal epithelium1. After day 55 of 
Figure 5 - Rat mammary extension 
of terminal end buds (TEBs) into the 
fat pad. Inset: Rat TEB with fuzzy 
halo (arrowhead), which contains 
inflammatory cells. 
Source: Comparative Anatomy and 
Histology: a mouse, rat, and human atlas, 
2nd edition. 
 
 
Figure 6 – Mouse mammary gland during the 
ovarian cycle. (A) - During estrus the mammary 
ducts are thicker, more abundant and have multiple 
side buds. (B) - During diestrus the glands regress to 
a simple branching structure with slender ducts with 
few side buds. 
Source: Comparative Anatomy and Histology: a mouse, rat, 
and human atlas, 2nd edition. 
 
 
(A) (B) 
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age, the number of alveolar lobules remains stable but can expand progressively over multiple 
estrus cycles6,20,25.  Lobules are the ultimate milk-producing functional units. 
 
 
 
During pregnancy, there is a rapid and continuous increase in the mammary gland epithelium 
during the approximately 19-21 days of pregnancy, with growth of both lobules and ducts 
occurring26.   
TEBs, if still present, rapidly divide to form alveolar buds, which give rise to alveoli and alveolar 
lobules. The alveolar lobules increase both in size and number until the space between ducts is 
almost filled with epithelium. Alveolar epithelium also shows hypertrophy, as the cells accumulate 
intracellular lipid and increase their rough endoplasmic reticulum and Golgi and secretory 
vesicles27. 
These lobules and mammary ducts contain myoepithelial and luminal epithelial cells, which 
are enclosed by a basement membrane that separates the epithelium from the surrounding 
connective tissue28,29. Myoepithelial cells form a continuous layer and secrete the continuous 
basement membrane2,9. Also, the myoepithelial cells surrounding alveoli during pregnancy and 
lactation form a discontinuous layer of stellate-shaped cells whose dendritic arms encircle the 
base of the alveolar epithelium and contract the alveoli during suckling29. The discontinuity of the 
myoepithelium can be seen by staining for myoepithelial cell markers as previously described6,7,22.  
During this time, there is a decrease in fat tissue and an increase of cellularity in the mammary 
gland stroma.  
Later, alveolar epithelium becomes presecretory and begins to produce large fat vacuoles and 
Golgi vesicles containing milk components, like lactose, protein and water. These components 
are released by apocrine secretion. The milk passes from the alveoli to the collecting ducts and 
out though nipple during nursing2. 
During lactation, mammary gland lumina is full of basophilic secretions and casein micelles in 
association with lipid globules. The alveoli are heterogeneous in both their luminal distension and 
the thickness of the luminal epithelium lining them, both within and between lobules30. 
Figure 7 - Schematic 
representation of the 
mammary gland of rats. 
Source: Boorman’s Pathology 
of Rat, 2nd edition. 
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The alveolar epithelium becomes presecretory and has a spongy appearance due to 
intracellular lipid and osmotic swelling of lactose-containing secretory vesicles14.  
The luminal alveolar cells produce large fat vacuoles (Figure 8) and Golgi vesicles containing 
lactose, protein, and water.  
 
 
 
 
 
 
 
 
 
 
The increased alveolar cell size causes the myoepithelial cell layer underlying the secretory 
alveolar epithelium to be even more discontinuous than in pregnancy22. 
The milk then passes from the lobules, to lactiferous duct (Figure 9). The lactiferous duct 
conveys milk through a constricted orifice from the lactiferous sinus to the nipple5. The lactiferous 
sinus has a distinctly convoluted lumen surrounded by two layers of cuboidal epithelium and a 
thick layer of eosinophilic stroma6.  
 
 
 
 
 
 
 
 
 
The epithelium of the nipple is continuous with the keratinized stratified squamous epithelium 
of the epidermis, although the opening to the nipple may be sealed from the external environment 
by a plug of epithelial cells or keratin6,31. 
 The transition from stratified squamous epithelium to two layers of cuboidal epithelium from 
the lactiferous sinus occurs in the lactiferous duct within the interior of the nipple5. The nipple also 
contains bands of smooth muscle that run parallel to the main lactiferous duct and 
circumferentially toward the base. The smooth muscle acts as erectile tissue and helps ejecting 
Figure 8 - Lactation in rat. Note the high 
volume of fat globules in the rat 
mammary gland. Images show 
secretory morphology comprised of 
acini with distended lumen that are filled 
with secreted milk and lined with 
flattened epithelial cells. 
 
Source: Comparative Anatomy and 
Histology: a mouse, rat, and human atlas, 2nd 
edition. 
 
 
Figure 9 - The mouse nipple and collecting 
ducts. The mouse nipple becomes prominent 
during pregnancy. Note the single lactiferous 
duct (LD). 
 
Source: Comparative Anatomy and Histology: a 
mouse, rat, and human atlas, 2nd edition. 
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milk2. During pregnancy the rodent nipples develop, protrude and the lactating mammary fat pad 
(MFP) becomes extensive (Figure 10). 
 
 
 
 
 
 
 
 
 
After weaning, which is usually complete in 20-22 days, there is extensive epithelial cell 
apoptosis or autophagy with loss of alveoli2. Apoptosis of blood capillary endothelial cells speeds 
up the regression of lactating ducts and remaining epithelial cells become non-secretory6,32,33,34.  
Lobules involute and become smaller but the number remains higher and more differentiate than 
in virgin females of the same age. At the same time is also notable the increase in adipocyte 
areas9. 
In nulliparous rats, after a year the mammary glands begin to involute, lobules become smaller 
and TEBs become terminal ductules. In males, the growth of ducts ceases at eight weeks of age, 
resulting in fewer subdivisions of ducts. The lactiferous duct ends near the epidermis blindly, as 
male rats lack nipples2. 
 
Rat estrus cycle and mammary gland physiology 
 
Female rats are poliestrics and spontaneous ovulators, showing successive estrus cycles, 
which are influenced by light, season of the year and age. With increasing age, female rats 
gradually develop irregular estrus cycles and eventually persistent anestrus24. 
Estrus cycles occur each 4-5 days and are divided in proestrus (12-18h), estrus (25-38h), 
metestrus (5-8h) and diestrus (47-58h)35. Westwood also considers the existence of an additional 
phase called anestrus, which is defined by ovarian inactivity, as observed when reproductive life 
is quiescent36. 
Every estrus cycle has temporal changes in the release of the three hypophysary hormones: 
Luteinizing Hormone (LH); Follicle-stimulating Hormone (FSH) and prolactin, as well as in the two 
ovarian hormones estrogen and progesterone. According to Robinson et al, the hypothalamus is 
responsible for the control of the release of FSH and LH from the adenohypophysis by the action 
of specific releasing and inhibitory substances37. These are secreted by the hypothalamic neurons 
Figure 10 - Mouse necropsy dissection. The 
pelt was degloved and reflected over the head. 
The subcutaneous MFP removed with the skin. 
Milk-filled ducts are visible as white branching 
lines. 
Source: Comparative Anatomy and Histology: a 
mouse, rat, and human atlas, 2nd edition. 
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and are carried from the hypothalamus by the hypothalamic– hypophyseal portal system37. Both 
FSH and LH are located within the same gonadotrophic cell, and the exogenous administration 
of GnRH (Gonadotrophin-realising Hormone) stimulates the releasing of both FSH and LH37,38. 
However, it is known that exists differential secretion of FSH and LH from the adenohypophysis 
gland and that it changes in the different stages of the estrus cycle. It appears that GnRH is critical 
for the basal and pulsatile secretion of LH, which is particularly evident during the preovulatory 
LH surge. In contrast, the secretion of FSH secretion is more independent from direct GnRH 
receptor signalling37,39. 
The secretion of FSH and LH is controlled by two functionally separate systems with two 
hypothalamic centres involved in this control37. The tonic system is responsible for the continuous 
basal secretion of gonadotrophin that stimulates the growth of both germinal and endocrine 
components of the ovary37. This system predominates during the luteal phase, when LH pulses 
are described as high amplitude and low frequency. The second system is the surge system, 
which controls the short-lived massive secretion of gonadotrophins, particularly LH, and is 
responsible for ovulation37. 
Progesterone inhibits the tonic mode of LH secretion40 by reducing LH pulse frequency. Thus, 
when the circulatory concentrations of progesterone fall, the release of LH from the anterior 
pituitary increase37. The increased frequency of LH pulses triggers the secretion of estradiol and 
stimulates the hypothalamic surge centre. Consequently, there is a surge of LH that will induce 
the final stages of follicular maturation, ovulation and the release of oocyte 41. The preovulatory 
LH surge triggers a series of cellular and molecular changes in the follicle that culminate in 
ovulation37 (Figure 11).  
Ovulation is a complex process, involving destruction of the follicle allowing the release of the 
oocyte and conversion of the follicle into the corpus luteum (CL). The fully formed CL consists of 
several different cell types: steroid-secreting large and small luteal cells, smooth muscle cells, 
pericytes, fibroblasts and endothelial cells42. The hormones that are most likely to be involved are 
prolactin and LH, with some evidence that they act in combination with each other. Prolactin plays 
Figure 11 - Estrus cycle of the rat. The 4-day 
estrus cycle of the rat (gray bars indicate night, 6 
p.m. to 6 a.m.), showing fluctuations in estrogen, 
progesterone, luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH). 
Source: A woman’s prerogative, 2005. 
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a critical role in maintaining the CL in rodents37,43,44. It can either be luteotrophic after mating or 
luteolytic in the absence of a mating stimulus. Prolactin acts as a luteotrophic hormone by 
maintaining the functional and structural integrity of the CL for 6 days after mating45. This action 
of prolactin, which has been described in the rat, is characterized by enhanced progesterone 
secretion46,47. Aside from its luteotrophic role, there is evidence in the rat that prolactin may be 
luteolytic as well47,48 by inducing programmed cell death in the CL49,50. 
During pregnancy, the presence of a functional CL producing progesterone inhibits the return 
to estrus, by exerting a negative feedback effect upon the hypothalamus37. In nonpregnant rat, 
estrus and ovulation occur at equally regular intervals, and the main control of this cyclical activity 
would appear to be the CL37. 
Luteolysis of CL is controlled by endometrial-derived PGF2α, transported directly from the 
uterus to the ovary. The mechanisms whereby PGF2α is transported to the ovary have not been 
conclusively shown in all species37. Luteal regression has two important parts: functional 
regression, in which the secretion of progesterone declines abruptly and structural regression, in 
which there is physical involution of the CL and regression of luteal tissue37. 
All these hormonal changes that occurs within the estrus cycle define a particular phase, that 
can be identified by vaginal smears, according with the cell types that are present: a) Proestrus 
is defined by the presence of round nucleated epithelial cells; b) Estrus is characterized by non-
nucleated, cornified epithelial cells; c) Metestrus typically has a low cell number, often with a lot 
of cell debris and d) Diestrus II contains mostly lymphocytes. This epithelium changes during the 
estrus cycle are induced by estrogen and progesterone51 (Figure 12). 
Through proestrus estrogen level increases and ovarian follicles grow fast52,53. During the night 
of estrus 10-12 h after the LH surge, ovulation occurs and, in the absence of mating at the time 
of ovulation, the CL are transiently functional and secrete a small amount of progesterone54. If a 
mate occurs, and ova are fertilized by sperm cells during the third hour after ovulation, CL life is 
extended throughout the first half of pregnancy54. During the second half, progesterone production 
takes place in the placenta52,53,55. 
Figure 12 – Vaginal smears stained by the Shorr method. Left to right: A: Estrus; B: Metestrus; C: Late 
Metestrus; D: Diestrus and E:  Proestrus. 
A: Estrus - clumps of enucleated acidophilic cells are observed. B: Metestrus - leukocytes are also observed. C: 
Late Metestrus - high number of leukocytes. D: Diestrus - small (SBC) and large basophilic cell (LBC). E:  
Proestrus - basophilic cells and pre-acidophilic cells (PAC). 
Source: The rat estrous cycle revisited: a quantitative and qualitative analysis, 2013 
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Persistent estrus is caused by high levels of estradiol and low levels of progesterone, while 
pseudo-pregnancy is characterized by low levels of estradiol, elevated levels of progesterone and 
high levels of prolactin, which extends the lifespan of the CL from the normal 2 days to 10–14 
days24,56. These estrus cycle irregularities and associated changes in endogenous concentrations 
of hormones are expected to influence on mammary gland proliferation.  
Multiple hormones and growth factors are involved in mammary gland development, such as 
estrogen, progesterone, prolactin, oxytocin, growth hormone, insulin like growth factor and many 
others (reviewed by Kleinberg 2008), but in association to estrus cycle, the ovarian steroid 
hormones estrogen and progesterone are essential to its growth57,58. 
Henning Hvid concluded that, in both young and mature rats, the percentages of proliferating 
epithelial cells of the mammary gland were strongly dependent on the estrus cycle. Significantly 
increased proliferation was observed during metestrus and proliferation in diestrus was 
significantly higher compared to proestrus in young and mature female rats24. Although one study 
reported high proliferation during metestrus and early diestrus, two other studies reported high 
proliferation during proestrus and diestrus24,59. 
Besides estrogen and progesterone, prolactin plays an important role in secretory activity of 
CL in ovaries as well in morphologic and functional properties of the mammary gland. The best 
characterised role for prolactin is its activity on the CL, particularly in rodents. It is essential for 
CL function and the inhibition of prolactin secretion leads to luteal regression44. This hormone has 
an important role in spontaneous mammary tumours in rats and studies have suggested that 
prolactin may be involved in mammary tumorigenesis 60 by promoting cell proliferation and 
survival61,62,63,64, increasing cell motility65 and supporting tumour vascularization60,66,67. 
Prolactin is a polypeptidic hormone synthetized by lactotroph cells, which comprise 30–50% of 
rat adenohypophysis and is released by a calcium-dependent exocytosis. Unlike other anterior 
pituitary hormones, which require hypothalamic stimulation, it appears that prolactin secretion 
from lactotrophic cells of the adenohypophysis gland is spontaneous37. In general, slightly more 
than half the lactotrophs of female rats secrete prolactin in a continuous pattern, while those of 
males secrete it in a discontinuous or intermittent pattern68. 
Prolactin may act as an autocrine/paracrine factor within mammary tissue as this hormone is 
mainly expressed in hypophysis but also in lactating mammary gland47,60,69,70,71. There is ample 
chronobiological evidence that the temporal organization of prolactin secretion is controlled by 
circadian input in rats47,72,73. Plasma concentrations of prolactin are the highest during sleep and 
the lowest during the waking hours47,74,75. Prolactin can be detected in epithelial cells of the 
lactating mammary gland43. Apparently, prolactin reaches the milk by first crossing the mammary 
epithelial cell basement membrane, attaches to a specific prolactin binding protein within the 
mammary epithelial cell and is ultimately transported by exocytosis through the apical membrane 
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into the alveolar lumen47,76,77. In addition to uptake of prolactin from the blood, the mammary 
epithelial cells of lactating animals are capable of synthesizing prolactin. The presence of prolactin 
mRNA78,69 as well as synthesis of immunoreactive prolactin by mammary epithelial cells of 
lactating rats was already described47,79,80. 
Serum prolactin levels are low during most of the estrus cycle, except in the afternoon of 
proestrus, when prolactin surge coincides with preovulatory LH surge47,81. LH surge is sharp and 
symmetrical, but the prolactin rise is triphasic, consisting of a sharp peak, a plateau, and a 
termination phase. In rodents, prolactin plays a significant role during the second half of 
pregnancy, replacing the suppressed hypophysary prolactin. Increased secretion of hypophysary 
prolactin during lactation causes inhibition of GnRH, LH and FSH, suppressing ovulation during 
lactation47,82. 
There are multiple physiological stimuli that regulate the secretion of prolactin, like nipple 
sucking during lactation, increased ovarian steroids, especially estrogen, both increasing prolactin 
release. These stimuli are sent to the hypothalamus, which produces Prolactin Releasing Factors 
(PRF) and Prolactin Inhibitory Factors (PIF) (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
In mammals, hypothalamus exerts a mainly inhibitory effect on the synthesis and secretion of 
prolactin, which is also influenced by other factors that are released by lactotroph cells of the 
adenohypophysis.   
Prolactin primarily acts through the prolactin receptor (PRLR), which belongs to the cytokine 
receptor superfamily47,66. The PRLR has multiple isoforms that are thought to arise by differential 
splicing. They have similar extracellular and transmembrane regions but have different 
intracellular domains60,66. The PRLR is detectable by immunohistochemical staining and its 
location staining also appears to differ in tumour cells in contrast with normal cells, such that 
Figure 13 - Circadian input 
and control of prolactin (PRL) 
secretion. 
Source: The Role of Prolactin in 
Men - Endocrinology & 
Metabolic Syndrome. 
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staining in normal cells is along the luminal cell border, while staining in malignant cells is primarily 
in the cytoplasm66,83.  
Jak-Stat signalling is the best characterized of the prolactin activated pathways. Jaks are 
nonreceptor tyrosine kinases, while Stats are latent cytoplasmic transcription factors composed 
of a modular structure of five domains. Phosphorylation of a tyrosine downstream of the SH2 
domain is critical for Stat activation84. Jak2, which is constitutively associated with Box 1 of the 
PRLR, is rapidly activated after receptor dimerization and phosphorylates tyrosine residues on 
the PRLR85. Stat proteins, attached by SH2 domains to phosphotyrosine residues on the PRLR, 
are also targets of activated Jak2, with Stat 5a and Stat5b being the primary mediators of PRL 
action. After phosphorylation, Stat proteins uncouple from the PRLR, homo- or heterodimerize 
and translocate to the nucleus, where they bind to Gamma Interferon Activated Site (GAS) 
elements and promote transcription of target genes86. Termination of signalling is an important 
component of hormone action. 
The PRLR may be associated with the estrogen (ER) and progesterone (PR) receptor 
expression and several in vitro studies have reported that long-term prolactin or estrogen 
exposure can increase both PRLR and ER expression62,87. Also, prolactin shares several 
characteristics with growth factors, including multiple extra-hypophysary sites of synthesis 88,89,90, 
wide distribution of receptors91, homology of the PRLR to those of the cytokine/hematopoietic 
growth factor family92, similarities in signal transduction pathways93 and mitogenic and 
morphogenic actions89,94. For knowledge, growth factors are emerging as important mediators of 
carcinogenesis and have been implicated in malignant transformation, tumour cell proliferation, 
and tumour progression95.   
The main regulation of prolactin is provided in the form of tonic inhibition by dopamine, which 
is secreted by tuberoinfundibular dopamine neurons (TIDA) through the hypothalamus-pituitary 
towards the lactotroph cells of the adenohypophysis. Dopamine exerts its inhibitory function 
through dopaminergic receptors type 2 (D2) in the membrane of the lactotroph cells. The 
activation of D2 receptors in the membrane of the lactotroph cell leads to inhibitory G proteins 
that are associated with the D2 receptor. This inhibitory G proteins inhibit adenylate cyclase 
(cAMP) and, at the same time, excites potassium channels that coupled to G0 proteins and block 
voltage-sensitive calcium channels, inhibiting secretion of prolactin16,47 (Figure 14).  
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Neurotransmitters such as norepinephrine, epinephrine, histamine and acetylcholine also 
modulate the secretion of prolactin. Histamine acts through its H1 and H2 receptors. Activation of 
H1 receptors has a stimulatory effect on prolactin secretion unlike H2 receptors, which inhibit the 
secretion of prolactin96,97. Acetylcholine acts on cholinergic receptors stimulating TIDA neurons, 
thus favoring the secretion of dopamine and the consequent inhibition of the secretion of prolactin.  
Other hormone that increases the secretion of prolactin is oxytocin. Oxytocin is synthesized in 
the paraventricular and supraoptic nuclei and is transported axonally to the neurohypophysis. The 
portal vessels that connect the neurohypophysis with the adenohypophysis allow its arrival in the 
lactotroph cells, where it promotes the release of prolactin. During pregnancy their concentration 
increases gradually until delivery, where there is a drastic decrease98. Nipple suction during 
lactation is the major prolactin secretory stimulus and overlaps over the control of its endogenous 
circadian secretion. The stimulation of the nipple causes a somatic response that is transmitted 
through the spinal cord and reaches the hypothalamus, where the release of serotonin and 
endorphin is increased. This causes a decrease in dopamine and an increase in the secretion of 
prolactin. The mammary stimulus also produces an increase in the release of oxytocin, which in 
the bloodstream reaches the breast where it induces the contraction of the myoepithelial cells, 
thus reducing the lumen of the milk ducts, promoting milk ejection47,98. 
 Finally, neuropeptides also play an important role in prolactin secretion. Thyroid stimulating 
hormone (THR), in addition to its specific function on the thyroid gland, stimulates the secretion 
of prolactin by the lactotroph cells of the hypophysis. TRH receptors in lactotroph cells are coupled 
to G proteins that activate phospholipase C, catalysing the hydrolysis of phosphatidylinositol 4,5-
bisphosphate generating inositol triphosphate and diacylglycerol. The inositol triphosphate (IP3) 
causes the release of calcium of non-mitochondrial origin, while the diacylglycerol (DAG) 
activates, through calcium, protein kinase C, which phosphorylates voltage-sensitive calcium 
channels by allowing its entry into the lactotroph cell, and thereby increases the secretion of 
prolactin47,81. 
 
 
 
Figure 14 – Feedback control 
of prolactin regulation. 
Source: Prolactin and dopamine: 
What is the connection? A Review 
Article, 2008 
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Spontaneous mammary gland tumor frequency and incidence 
 
Mammary gland fibroadenomas are the most common spontaneous subcutaneous tumor of 
domestic rats99. This type of tumor is associated with hyperprolactinemia in some strains of 
laboratory rats100,101,102,103. 
As referred previously, prolactin secretion increases due to a decrease in the secretion of 
dopamine from the hypophysary gland in geriatric rats104 and persistent low concentrations of 
progesterone, constant estrus, or cessation of ovulation in female rats105. In some laboratory rat 
strains, including the Sprague-Dawley (SP)104, Fisher106 and Wistar107,108 strains, hypophysary 
gland adenomas develop in more than 80% of rats with more than 24 months old.  Some geriatric 
rats with mammary gland fibroadenomas develop concurrent prolactin-secreting hypophysary 
adenoma (chromophobic hypophysary adenoma)105,104,107,108.  
The incidence of spontaneous mammary gland tumors in rats is high, ranging from 30% to 
67% in female SD rats109. Adenocarcinomas represent less than 10% of spontaneous mammary 
gland tumors in rats105.  Authors Noble and Cutts found that, in a group of 150 female SP rats 
with an average life span of 2 years, mammary tumors accounted for 95% of the total tumours 
found in 54% of the animals110. Also, incidence rate of mammary gland tumors in female rats that 
are ovariohysterectomized at 90 days old was significantly smaller than older sexually intact 
female rats, and reproductive sterilization of rats between 5 and 7 months of age reduced the 
incidence rate of spontaneous subcutaneous (SC) tumors from 73.8% to 5.3%111. Concomitant 
abnormalities in companion rats with spontaneous mammary gland fibroadenomas are poorly 
described. 
According to Poteracki’s study, mammary fibroadenomas were the most common mammary 
tumor, occurring in 36.1% and 2.6% in females and males, respectively. On the other hand, 
mammary adenocarcinoma occurred in 6.7% of females. Mammary tumors accounted for 55% of 
neoplasms in the integument and 95% of these occurred in females112. 
Vergneau-Grosset et al described the prevalence and concomitant abnormalities of the various 
types of mammary gland tumors in companion rats.  From the 105 SC masses initially detected 
in 100 rats, the most prevalent SC mass identified was mammary gland fibroadenoma, which 
comprised 53% of all masses, followed by mammary gland carcinoma (12%). Overall, 25% of the 
masses were malignant. At the time of the study, 37 subsequent SC masses appeared: 68% were 
benign and 32% were malignant. From this 68% of benign masses, 65% were mammary gland 
fibroadenoma, and from the 32% of malignant masses, 16% were mammary gland carcinoma. 
Fibroadenoma was the most common neoplasm identified in the axillary region113. 
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Concomitant hypophysary tumor was identified in most rats with mammary gland 
fibroadenoma (75%) and other types of mammary gland tumors (59%). Also, 40% of the rats with 
mammary gland fibroadenoma had concomitant reproductive tract abnormalities113.  
Histologic diagnosis was also associated with sex. Mammary gland fibroadenoma is more 
likely to develop in sexually intact females and males than in neutered rats113. Additionally, eleven 
of the thirteen malignant mammary tumors were identified in sexually intact females. In sexually 
intact males, most initial SC masses were non-mammary gland tumours113.  
Curiously, of five spayed female rats present in one study, one had a mammary gland 
carcinoma, one had a hemangiosarcoma and the remaining had mammary gland fibroadenomas. 
The three spayed female rats that developed mammary gland fibroadenoma underwent 
ovariohysterectomy at 3.5, 5, and 12 months old, respectively113. This study also concluded that 
the prevalence of mammary gland carcinoma in the companion rats was 3 times greater than the 
4% reported for sexually intact and ovariectomized SD rats in laboratory105. 
In rats that received no adjunctive treatment after excision of a mammary gland fibroadenoma, 
a second fibroadenoma was detected 1 to 8 months after initial excision, at a median of 4.5 
months after surgery113. 
Harleman et al reviewed the incidence and coincidence of uterine and mammary tumors, 
suggesting a strong inverse relationship between uterine and mammary tumors in Wistar and SD 
rats. They settled that there were differences in background incidence data between the two 
strains. The Wistar rat had an evidently lower incidence of mammary tumors (24%) compared 
with SD rats (58%). In contrast, the Wistar rat had a markedly higher spontaneous incidence of 
uterine tumors (5%) compared with the SD rats (0.9%). In both strains, the occurrence of uterine 
tumors arises predominantly in animals without a mammary tumor, being more pronounced in 
Wistar rats. For this strain, there was a strong evidence of an inverse relationship between 
mammary and uterine tumors114. 
Once again, the driving factor for this response is likely to be prolactin. The increase in 
circulating prolactin is directly associated with an increase in the incidence of mammary tumors, 
as prolactin is the major promotional driver of mammary tumors in this species114,115,116. As 
previously stated, prolactin is luteotropic in rats and promotes progesterone production of the CL 
after ovulation and sustains gestation. During the luteal phase of the estrus cycle, the CL 
produces large quantities of progesterone, which antagonizes estrogenic stimulation of uterine 
growth114,117. Therefore, over a series of cycles, inhibition of prolactin results in an increased 
estradiol:progesterone ratio in rats. Estrogen has a trophic effect in the uterine endometrium, 
promoting an increased incidence of uterine tumors114. 
Dinse et al recognised that several types of tumors were common in both Fischer and SD 
female rats. Among eighteen studies, they found that mammary gland fibroadenomas ranged 
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48% in Fischer rats and 67% in SD rats and mammary gland carcinomas ranged 2% and 10% in 
Fischer and SD, respectively109. 
 
Spontaneous mammary gland tumor etiology 
 
It is known that female intact rats are more commonly affected by spontaneous mammary 
tumors than male rats. Mammary tumors develop in 30%–90% of intact female rats (depending 
on the strain), and 0.5%–16% of intact males. Also, multiparous rats appear to have higher 
incidence of mammary tumors than nulliparous rats118. 
So genetic predisposition seems to be an important factor. Spontaneous mammary tumors 
develop in females of various strains of rats, such as August, Albany-Hooded, Copenhagen, 
Fisher, Lewis, Osborne-Mendel, Sprague-Dawley (SD), Wistar, and Wistar/ Furth3. The Fischer 
strain is generally less susceptible than the Sprague-Dawley and Wistar-derived strains1.  
Age is one of the main factors for the development of mammary tumors. They are uncommon 
in rats younger than 1 year of age and its incidence increase markedly after about 18 months of 
age119. Obesity and high-fat diets are associated with increased incidence of spontaneous and 
chemically-induced tumors. 
Concomitant pathologies are common, with hypophysary adenoma being the principal 
disease. Literature data clearly demonstrate that most rat hypophysary adenomas are prolactin-
positive114,120. They are functional prolactin-producing tumours and, because of the rapid 
discharge of the hormones they produce, they can be also called chromophobic hypophysary 
adenomas114,121. Studies in rats show that many animals with hypophysary adenomas have high 
levels of circulating prolactin and that this correlates with the size of mammary tumors114,122. 
Environmental conditions are also significant. Some authors suggest that chronic stress can 
influence the development of cancer by deregulation the corticosteroids levels. However, it can’t 
be concluded that stress itself is a primary factor for the development of tumors in rats. One study 
was made to evaluate the effect of various light/dark regimens on the survival, life span and 
tumorigenesis in rats. Nocturnal rise of melatonin (produced by the pineal gland and released 
during the dark periods of the night) is abolished or substantially decreased in animals exposed 
to constant light, so they concluded that female rats exposed to constant illumination leaded to 
disturbances in estrus function and spontaneous tumor development. This study was the first to 
show that the exposure of male rats to constant illumination accelerated the development 
spontaneous tumors123,124.  
Other review reported that suppression of pineal function, either by pinealectomy or with 
appropriate light exposure, enhanced tumor incidence, number, and size and reduced tumor 
latency. These antitumoral actions of the pineal gland may be related to its ability, via the secretion 
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of melatonin, of downregulate some of the hypophysary and gonadal hormones, which control 
mammary gland development and are also responsible for the growth of hormone-dependent 
mammary tumors124. 
In a recent study, authors proposed that infant temperament predicted life span in female rats 
that developed spontaneous tumors125. They found that, for females that developed either 
mammary or pituitary tumors, and were reluctant to explore a new environment in infancy died 
approximately 6 months earlier than their exploratory sisters. Also, they have shown that female 
temperament may have the greatest effect on when tumors first develop, as opposed to the rate 
at which tumors proceed following tumorigenesis125. 
 
Clinical signs of mammary tumors 
 
When owners come to the clinic, they may describe that the animal is lethargic, has increased 
appetite without gaining weight, or has decreased appetite and lost some weight. The weight loss 
despite good appetite may occur because nutrients are supporting the growth of the mass. 
Others notice a small subcutaneous mass, although rats can reach the clinic with ulcerated 
masses that can be up to one-third of the animal body weight, causing a decreased mobility. 
(Figure 15). Complications of large ulcerated mammary tumors are potential risk for blood loss, 
anaemia, necrosis and secondary infection, which can lead to septicaemia, organ failure, and 
possible death126. 
 
 
 
 
 
 
 
 
Because mammary tissue is so extensive, tumors can develop anywhere from the cervical 
region to the base of the tail. These tumors grow rapidly, becoming very large within weeks.  
Normally, after clinical examination of the animal and palpation of the mammary gland chain, 
it can be felt single or multiple, small or large, spherical, soft to firm subcutaneous painless 
masses that usually are not attached to deeper structures. Less spherical masses adherents to 
underlying musculature may be suggestive of malignancy. Sometimes, mammary gland infection 
or abscesses can also be present127.  
 
Figure 15 - Mammary tumor in a 
non-neutered female Wistar rat. 
Original picture 
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Diagnosis of mammary tumor and differential diagnosis 
 
Usually, when a mass appears along the mammary gland chain, a fine-needle aspiration 
should be performed. However, in rats this method is considered unreliable, since rat’s tumors 
have poor exfoliation properties and necrotic areas that contain inflammatory cells may mask the 
neoplastic element of interest128. The gold standard method is histopathology, so the veterinary 
who performs the excisional biopsy of the mass, should kept the tumor in formaldehyde for later 
analysis129. If the veterinary suspects of malignant mammary tumor, a thoracic radiography should 
be performed, although metastasis of these tumors are considered rare126,130. 
Regarding differential diagnosis, one should consider SC abscess (that can be secondary to 
cage mate aggression or trauma), hematoma, mastitis (in which the affected glands could be 
warm, swollen and/or with a haemorrhagic discharge) and cyst or hyperplasia of the mammary 
gland. It is important to diagnose mammary hyperplasia, since it can progress to mammary tumor. 
Considering mammary tumors,  besides fibroadenoma the clinician should consider the possibility 
of being a lipoma, sarcoma, squamous cell carcinoma, mast cell tumor or lymphoma127. 
Histopathology evaluation is essential to characterize mammary tumors in rats, since they are 
classified according to epithelial components and stroma involvement. Fibroadenomas are the 
most common benign neoplasm of the mammary gland of the rat. They are round to irregularly 
oval masses, generally greater than 5 mm in diameter, reaching up to 8 cm in diameter1. They 
are well-defined and may be encapsulated. On cut section, tumors are lobulated with regions of 
highly fibrous to glandular tissue. Histologically, alveoli and ductules are surrounded by prominent 
mature connective tissue stroma. The alveoli within the lobules are usually well formed and lined 
by cuboidal epithelial cells, frequently with prominent vacuoles in the cytoplasm. Smaller 
fibroadenomas often have a lobular growth pattern. This pattern is not so evident in larger 
neoplasms, where widely separated ductules are surrounded by concentric layers of dense 
connective tissue1. Fibroadenomas are composed of glandular epithelium (ducts, ductules, and/or 
alveoli) and fibrous connective tissue, with varying proportions of epithelial and fibrous 
components, which can vary the texture and consistency of the mass. Generally, epithelium is 
uniform without atypia or stratification, but if it occurs is only focally. Mitotic figures are rare and 
atypical cells do not constitute an expanding mass. Areas of necrosis may be present in the centre 
of the mass1.  
The second most common tumors are malignant adenocarcinomas, round or irregular masses, 
greater than 5 mm in diameter with some grade of local invasion, that rarely metastasize. They 
are relatively poorly demarcated and may invade adjacent tissues, like muscle or skin1. These 
tumors where previously classified as “cribriform”, “tubular”, “anaplastic adenocarcinoma”, 
“papillary” and “comedo carcinoma”, depending of its shape. They can arise from focal 
 
 
20 
 
hyperplasia with atypia in ducts, ductules or alveoli and foci of atypia in adenomas or 
fibroadenomas. It consists of epithelium arranged in alveolar, ductular, papillary or solid structures 
or frequently combinations of these structures1. The epithelial cells form single or multiple layers 
and small compact nests or nodules of neoplastic cells are sometimes present.  
The more malignant neoplasms often have solid sheets and nodular masses of neoplastic 
cells. The neoplastic epithelium exhibits cellular atypia, consisting of altered size or shape of cells, 
chromatin content of nucleus, prominent nucleoli, altered nuclear/cytoplasmic ratio and altered 
staining quality of cytoplasm1. Pleomorphism or diffuse stratification is also present and areas of 
necrosis, skin ulceration and haemorrhage may also occur1. When present or associated with 
adenoma or fibroadenoma, the malignant component constitutes an expanding mass that 
compresses and displaces the benign components. 
Other forms of mammary tumors are described in figure 16, since histologic diagnosis of SC 
mammary masses is important to establish the treatment protocol, prevent mass recurrence and 
predict the prognosis. 
 
Treatment, prognosis and prevention 
 
There are two types of treatment that can be applied in rat mammary tumor: medical and 
surgical treatment. Regarding medical treatment, it comprises dopamine agonists, hormonal 
implants and chemotherapy. Knowing that prolactin influences the incidence of mammary tumors 
via a direct trophic effect114 and that that dopamine decreases prolactine release throught the 
activation of dopamine receptors type 2 (D2), the use of dopamine agonists is a predictable 
therapeutic option131. Cabergoline is one of this drugs approved for veterinary use in Portugal. 
Nagasawa concluded that the administration of cabergoline prevented the development of 
spontaneous mammary gland fibroadenoma in some strains of laboratory rats100. However, in 
another study, tumors recurred at the same location within 1 to 9 weeks after the administration 
Figure 16 – Mammary tumor 
classification in domestic rats. 
Source: Significance of Rat Mammary 
Tumors for Human Risk Assessment, 2015. 
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of the dopamine agonists was discontinued132. Cabergoline is prefered to bromocriptine, due to 
its longer duration of action. Results of a study indicate that administration of 0.6 mg of 
bromocriptine/kg, PO to laboratory rats suppressed serum prolactin concentration for only 6 
hours, whereas administration of the same dose of cabergoline suppressed serum prolactin 
concentration for up to 6 days133. Dopamine agonists are also associated with a reduction in the 
incidence of hypophysary adenomas and hyperplasia, but unfortunatly also increase the 
incidence of uterine tumors134,135,136. 
Other treatment to prevent and stabilize the growth of mammary tumors is the application of 
deslorelin implant. This implant (Suprelorin® Virbac) is usually applied subcutaneously in the 
interscapular zone (Figure 17). Deslorelin is a GnRH agonist and exert its mechanism of action 
through the desensitization and downregulation of adenohypophysis GnRH receptors. 
 
 
 
 
 
 
 
 
 
In male rats, administration of deslorelin results in internalization of GnRH receptors and 
downregulation, inhibiting secretion of FSH subunit β by hypophysary gonadotrophs137. It is 
assumed that there is a transient increase in the secretion of LH and FSH that lasts for 
approximately 2 weeks following the administration of a deslorelin implant in rats138.  However, its 
use as an adjunctive treatment for mammary gland fibroadenoma in rats has not been described. 
Instead, it has been used as a contraceptive in male and female rats since 2011, although its 
reversibility remains unidentified138,139. 
According to Alkis, after the implantation of a 4.7-mg deslorelin implant in rats, serum 
progesterone and estradiol 17β concentrations are suppressed for up to 12 months 139. However, 
there are some type of tumors that have a more aggressive phenotype, and its growth can 
become  independent from hormone influence140. 
In a recent study, a 12-month-old sexually intact female rat with mammary gland fibroadenoma 
received a deslorelin implant (4.7 mg, SC) five weeks after surgical excision of the tumor. No 
subsequent SC masses were detected during the 12 months after administration of the implant. 
In the same study, another rat received a second deslorelin implant 15 months after the first, 
because of the emergence of a new SC mass. The second implant stabilized growth tumor for 
Figure 17 – Appling a subcutaneous 
deslorelin implant to a rat. 
Original picture 
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only 5 months, after which the mass began to increase in size113. Authors suggested that the 
increase of the mass may have happened due to premature loss of efficacy by the implant, a 
decrease in the responsiveness of the tumor following the introduction of the second implant, or 
evolution of the tumor receptors toward an aggressive phenotype that could not be regulated by 
reproductive hormones113. 
There are few studies on the efficacy of chemotherapy in the treatment of spontaneous rat 
mammary tumors. It is known that in dogs and cats, chemotherapy is administered based in a 
protocol treatment for mammary tumors. One of the protocols is to administer orally a tyrosine 
kinase inhibitor, like toceranib, together with a non-steroidal anti-inflammatory drug, such as 
meloxicam. The dosages for rats are not standardized and are usually extrapolated from other 
species’ recommendations130. 
 Cisplatin, a platinum-based chemotherapeutic agent, has been used for treatment of 
induced mammary tumors in rats, and the results showed a decrease in the development of these 
tumors. In other study one rat received intralesional cisplatin (1.6 mg, each week). However, that 
rat experienced two excisional biopsies and had recurrence of the mammary gland carcinoma in 
the inguinal area twice. The last recurrence was only 4 days after the last intralesional cisplatin 
treatment, and that rat was humanly euthanized. The authors could not draw any conclusions 
regarding the effectiveness of cisplatin113. 
Besides medical treatment, in most cases it is necessary to perform surgery. Surgical 
treatment implies the excision of the mass or masses, and some authors suggest performing an 
ovariohysterectomy together with the nodulectomy in order to minimize tumor recurrence105. This 
last procedure is recommended when excision of the entire mammary chain is not possible due 
to the extension of mammary tissue. The anaesthetic risk must be taken into consideration, as 
well as the physical condition of the patient. The removal of mammary tumors must be done as 
soon as it is diagnosed, and surgery time must be minimized.  
In the peri-operatory time rats should receive supportive treatment, both pharmacological and 
nutritional. Pharmacologically, analgesic, antibiotic and anti-inflammatory drugs should be 
administered to rats, but before considering surgery the patient must be stabilized, so 
subcutaneous (SC) hydration and a good plane of nutrition are necessary. If the rat does not eat 
by itself, it is necessary to force feed. Atropine can be administered to prevent bradycardia and 
secretions, but the analgesic should be administered before, during and after surgery and EV or 
SC fluids should be provided. Patient temperature must be checked regularly, so a heating mat 
can be used to produce heat, as hypothermia is one of the main causes of death during surgery.  
Preanesthetic medication should be given, but during the surgery anaesthesia should be 
maintained with volatile anaesthetics. Previously to incision, the surgeon must decide if considers 
the mass as a benign or a malignant tumor, because in benign masses the skin is preserved, 
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unlike ulcerated large masses, or suspected malignant masses, in which the removal of the tumor 
is via an elliptical incision with wide margins127. As the majority of the tumors are fibroadenomas, 
we are going to discuss the approach of a benign mass further.  
The animal must be positioned in dorsal recumbency and the surgical area must be prepared 
aseptically. Then, the surgeon can block local nerves to prevent pain in the site of incision. The 
incision is performed and the mass should be debrided. If the tumor is well irrigate, ligating vessels 
prevents bleeding and helps haemostasis. The skin must be closed with an absorbable suture 
yarn, with a discontinuous pattern or intradermal continuous pattern, since visible skin sutures will 
probably be chewed by the patient.  Tissue glue is also a good option126. The excised mass should 
be kept in formaldehyde for further analysis. 
Prospects of recovery are favourable if the animal does not have any concomitant pathology 
(e.g. hypophysary adenoma), but still suture dehiscence and infection can occur. Mammary 
tumors frequently reoccur within months, so veterinary should advise the rats owners to monitor 
for mammary masses in patients and to have regular check-ups127. 
To prevent mammary tumors, early ovariohysterectomy or ovariectomy is indicated, as 
mammary tumors develop in 30%–90% of intact female rats. If the patient has a mass but the 
owner does not want perform surgery, the veterinary should suggest a deslorelin implant to slow 
down the growth of the mass. 
Owners should provide low-fat nutritious diet and prevent obesity. Food ad libitum should not 
be given. Some vegetables and fruits actively prevent formation of tumors, such apples, broccoli 
and brussels sprouts, because of the phytochemicals they possess. These phytochemicals have 
antioxidant activity against free radicals and act on the regulation of gene expression in cell 
proliferation, cell differentiation, oncogenes and tumor suppressor genes. They also induce cell 
cycle arrest and apoptosis141.   
Finally, owners should be able to select tumor free parents, and choose male over female rats. 
Rats must be kept in pairs to reduce environmental stress and provide exercise and 
environmental enrichment. Further studies are necessary to investigate adjunct treatment 
protocols, including the use of chemotherapy and GnRH agonists for companion rats with 
mammary gland fibroadenoma or other SC masses113. 
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CLINICAL CASE 
 
Sirius was a standard Rattus norvegicus, mink, self-dumbo, intact female, two years old and 
503g in weight (Figure 18). 
 
 
 
 
 
 
 
 
The reason for consultation was the growth of a previous right cranial thoracic mammary 
nodule. Sirius lived with more rats in a cage and had access to the outside, always supervised, 
with ad libitum access to food and water. 
Regarding Sirius medical history, five months ago she had been given a hormonal implant of 
deslorelin because she had a growing nodule in the right cranial thoracic mammary gland. The 
growth of the nodule was stabilized for 5 months after the implant.  
Examining the general state, one can say that she had normal mental state and balanced 
temperament. The degree of dehydration was <5%, body condition 6/9, respiratory movements 
with frequency within the parameters.  
At physical examination, Sirius demonstrated difficulty in locomotion and the owner reported 
that she had difficulty raising the cage to feed. At palpation, the mass was mobile, painless, with 
fibrous consistency and well-defined limits, 5cm x 5cm in diameter. No further analysis was 
performed and Sirius was indicated for nodulectomy. 
The list of problems was cranial thoracic mammary nodule. The differential diagnosis was 
mammary hyperplasia. No additional tests were performed, so the final diagnosis was not 
achieved because the owner did not want the mass to be analyzed histopathologically.  
Nevertheless, the treatment was surgical. Since the incidence of mammary tumors is high in 
intact females and most are fibroadenomas, Sirius was subjected to nodulectomy. The patient 
was hospitalized and medicated with: tramadol (Tramal® Grünenthal inj. 50mg/ml) 0,2ml/kg SC 
bid as painkiller, meloxicam (Acticam® Ecuphar 5mg/ml) 0,1 ml/kg SC sid as anti-inflammatory 
and enrofloxacin (Baytril® Bayer 5%) 0,2 ml/kg SC bid as antibiotic, in appropriate doses. 
Before surgery, the patient was stabilized with SC hydration and a nutrition plane. Analgesia 
with an opioid was provided before, during and post-surgery, as well as hydration, via intravenous 
Figure 18 - Sirius, a Rattus 
norvegicus with a clear 
mammary mass 
 
 
 
 
25 
 
(IV) catheter or SC126. Finally, atropine 0,5mg/kg was given intramuscular (IM) in a dose of 
0,8ml/kg.   
The pre-anaesthesia was given to Sirius: Tramadol (0,2 ml/kg) and Medetomidine (Domitor® 
Pfizer 1mg/ml) 50 µg/kg via IM plus Ketamine (Imalgene® Merial 100mg/ml), 2–4 mg/kg via IM. 
During anaesthesia the patient was on oxygen mask linked to volatile anaesthesia (Isoflurane) 
and oxygen (Figure 18). 
 
 
 
 
 
The animal was positioned in dorsal recumbency and the surgical area was prepared 
aseptically with alcohol and chlorhexidine (Figure 19). 
 
 
 
 
 
Previously to the incision the surgeon decided to treat the mass as a benign tumor and 
performed local blocks with lidocaine 5% SC along the incision line126 (Figure 20). Then, a single 
incision was performed and debridement of the mass was made with a blunt tipped scissor (Figure 
21). The mass was extirpated and the skin was closed with an absorbable suture yarn, in an 
intradermal continuous pattern (Figure 22). 
 
 
 
 
 
 
 
 
Figure 18 – Sirius pre-anaesthesia 
with oxygen mask. 
 
 
Figure 19 - Shaving the 
mass to further cleaning. 
 
Figure 20 - Infiltration of the 
incision site with lidocaine. 
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At the end of surgery, atipamezole (Antisedan® Zoetis 5 mg/ml) was administered IM at the 
same volume of medetomidine, to revert its effects. The patient continued with supportive 
treatment during the days it was hospitalized.  
When Sirius went home she showed some signs of recovery but did not feed properly. The 
tutors reported that unfortunately she continued to refuse food, and eventually died fifteen days 
after the surgery.  
 
  
Figure 21 – Blunt dissection of 
the tumor. 
 
 
Figure 22 – Closure of the skin 
with an intradermal patter. 
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CONCLUSION 
 
      This work aimed to systematize the existing knowledge about a pathology that frequently 
affects domestic rats - mammary tumors. Their incidence ranges from 30% to 67% in female SD 
rats and the most frequent tumors are fibroadenomas. Numerous factors potentiate its onset, but 
high levels of circulating prolactin and estrogen are generally implicated.  
Cytology is not a reliable method to diagnosis these masses, but since most owners do not 
want to send excisional biopsy to analysis, these mammary tumors diagnosis is usually 
presumptive. 
Treatments are limited, so it is necessary to carry out further studies to test new drugs that can 
stop tumor evolution. There is the need to conduct more studies to test the influence of deslorelin 
implants in mammary tumor, as well as test chemotherapy that could help increase the average 
life expectancy. 
Prevention remains the most effective weapon but has been neglected, so owners should be 
advised to timely spay their pets in order to reduce the probability of mammary tumor appearance.  
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